Staff Physician and Associate Director
Center for Immuno-Oncology Research
Despite decades of efforts to improve cytotoxic chemotherapy combinations for patients with lung cancer, we have made very modest improvements in outcomes and the malignancy remains a leading cause of cancer-related death worldwide. Recent advances in immunotherapies that use agents to circumvent critical tumor immune evasive pathways, such as PD-1/PD-L1, have shown promise. Three drugs targeting these pathways are now approved by the FDA for use in patients with non–small cell lung cancer (NSCLC): nivolumab (Opdivo), pembrolizumab (Keytruda), and atezolizumab (Tecentriq). However, most patients with NSCLC who are treated with immunotherapy do not respond to these therapies.
... to read the full story